Southern cross equites have a valuation of 63cents.
"Target price $0.60. Our CVac valuation plus our assumption of increased dilution
resulted in our valuing PRR at base case $0.63 per share and optimistic case $1.12
per share. Our 60 cent 12-month target price sits at the lowpoint of this range.
Strong potential upside. We regard the current (ie 28 May 2010) market
capitalisation of Dendreon on Nasdaq of US$5.9bn as indicative of the potential
upside from CVac once PRR begins to gain in sentiment terms."
63c - $1.12 valuation
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.015(4.69%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.5¢ | 32.0¢ | $1.303M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 29843 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 105523 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |